Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
Status:
Not yet recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and tolerability of PH94B with repeated dosing over a period
of up to 12 months. Participating subjects will use PH94B up to 4 times a day when they
encounter anxiety-provoking situations in daily life. Safety and tolerability of PH94B (≤ 4
doses per day up to 12 months) will be assessed and summarized during monthly visits from
baseline (Visit 2) to end of treatment (Visit 14) in AEs, laboratory values, 12-lead ECGs,
physical examinations, and vital sign assessments following exposure to PH94B.